|Videos|August 18, 2022
Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM
Author(s)Shaji Kumar, MD, Jonathan L. Kaufman, MD
Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.
Episodes in this series
Related to this article
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
3
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma
4
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
5